Dogwood Therapeutics Inc. announced the enrollment of the first 100 patients in its ongoing Phase 2b HALT-CINP clinical trial evaluating Halneuron® for chemotherapy-induced neuropathic pain (CINP). The study is assessing the safety and effectiveness of Halneuron® compared to placebo in cancer patients with neuropathy resulting from previous platinum or taxane-based chemotherapy. Participants receive eight subcutaneous doses over 14 days, with follow-up at 28 days. The primary endpoint is the change in weekly average daily pain intensity scores from baseline to week four. An interim sample size analysis is scheduled for the fourth quarter of 2025, and final trial data are expected by mid-2026. Results from the study have not yet been presented.